Strategic acquisition Kandu Health recently acquired Neurolutions Inc., expanding its portfolio in neurorehabilitation devices. This presents cross-sell opportunities to integrate device-based therapies with their digital health platform and offer a more comprehensive stroke recovery solution.

Series B momentum With a $30M Series B closed in 2025 led by Ally Bridge Group and AMED Ventures, Kandu Health demonstrates strong investor confidence and a scalable growth trajectory, signaling readiness for enterprise partnerships, larger pilots, and potential co-development deals.

Clinical leadership Having a Chief Medical Officer with cerebrovascular expertise and a CEO appointed in 2023 signals credibility in clinical outcomes and regulatory alignment, making it easier to engage hospital systems, payers, and rehab programs seeking proven stroke recovery solutions.

Healthy tech stack The stack includes HIPAA-compliant data practices, OAuth, Jira, and JSON-LD, indicating readiness for enterprise deployments, data sharing with partners, and scalable product integrations with health systems and rehabilitation devices.

Growth-ready partnerships As a subsidiary of Imperative Care, Kandu Health sits within a network focused on disease detection through recovery, offering synergistic collaboration with vascular and stroke care players, device manufacturers, and health systems for bundled solutions.